Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Allergy Therapeutics ( (GB:AGY) ) is now available.
Allergy Therapeutics reported positive biomarker data from its Phase I/IIa PROTECT trial of VLP Peanut, showing strong and consistent immunomodulating effects in peanut-allergic subjects. Higher doses produced marked reductions in basophil sensitivity and IgE-Fab binding to Ara h2, alongside significant increases in protective Ara h2-specific IgG and reduced skin prick test wheal sizes versus placebo.
External experts from Imperial College London and King’s College London highlighted that the degree of immune modulation seen after just three injections over two to three months rivals or exceeds responses typically achieved only after prolonged oral immunotherapy. Management said these interim results provide clinical proof of concept and, together with previously reported safety and tolerability, support rapid progression to a Phase IIb trial that will refine dosing and test efficacy via food challenges, potentially reshaping the treatment landscape for peanut allergy if later-stage trials succeed.
The most recent analyst rating on (GB:AGY) stock is a Sell with a £11.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The score is driven primarily by very weak financial performance (declining revenue, large losses, negative cash flows, and negative equity). Technicals are mixed with oversold signals but still negative momentum, and valuation is constrained by a negative P/E and no dividend support.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics plc is a fully integrated commercial biotechnology company specialising in allergy immunotherapies, with a focus on developing treatments for conditions such as peanut and other food allergies. The Group targets patients in major markets including the U.S. and Europe, aiming to offer alternatives to current oral and monoclonal therapies with shorter, injection-based regimens.
Average Trading Volume: 318,944
Technical Sentiment Signal: Buy
Current Market Cap: £747.2M
Learn more about AGY stock on TipRanks’ Stock Analysis page.